2024-05-13T13:26:48-05:00 2023-12-31 233018514 DUNLAPSLK PC 1300 HORIZON DRIVE SUITE 106 CHALFONT PA 18914 990 2023-01-01 232740843 ALTERNATIVES RESEARCH AND DEVELOPMENT FO ALTE 2158878076 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 SUE A LEARY PRESIDENT 2158878076 2024-05-13 1 SUE LEARY 999009999 0 JULIA L DAVIS P00163568 2675943755 2024-05-10 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z SUE A LEARY 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 2897618 0 X WWW.ARDF-ONLINE.ORG X 1993 PA ARDF PROMOTES AND DEVELOPS ALTERNATIVE SCIENTIFIC SOLUTIONS TO THE PROBLEM OF ANIMAL TESTING. 7 6 1 10 0 0 333654 77619 0 0 526141 673249 0 0 859795 750868 270142 266937 0 0 45870 47461 0 0 3636 265256 320027 581268 634425 278527 116443 11875792 14204946 42464 16178 11833328 14188768 X THE MISSION OF THE ARDF IS TO FUND AND PROMOTE THE DEVELOPMENT, VALIDATION AND ADOPTION OF NON-ANIMAL METHODS IN BIOMEDICAL RESEARCH, PRODUCT TESTING, AND EDUCATION. 0 0 478143 266937 THE "ANNUAL OPEN" GRANT PROGRAM FUNDS INNOVATIVE ALTERNATIVE METHODS TO REDUCE OR REPLACE ANIMAL USE IN RESEARCH AND TESTING.2023'S FUNDED PROJECTS WERE FOR SCIENTIFIC RESEARCH: 1.) USING HUMAN LUNG SLICES TO STUDY THE RELATIONSHIP BETWEEN CIGARETTE SMOKE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), AND TO TEST DRUG CANDIDATES FOR TREATING COPD. 2.) USING HUMAN GINGIVAL SLICES TO DEVELOP A NON-ANIMAL MODEL FOR STUDYING ORAL INFLAMMATORY DISEASES. 3.) USING HUMAN BRAIN ORGANOIDS TO EXAMINE THE EFFECTS OF SEX HORMONES ON NEURODEVELOPMENT IN ORDER TO UNDERSTAND HOW ENDOCRINE DISRUPTORS CAN ALTER IMPORTANT PROCESSES IN THE DEVELOPING BRAIN. 4.) HUMAN-BASED IN VITRO 3D MODEL OF BONE FRACTURE HEALING TO STUDY THE INITIAL BLEEDING AND HEALING PROCESSES THAT OCCUR DURING BONE FRACTURE. 5.) PANCREATIC ISLET ORGANOIDS-ON-A-CHIP SYSTEM TO STUDY TYPE 1 DIABETES, PROVIDING A NOVEL PLATFORM THAT COULD REPLACE THE USE OF ANIMALS IN IDENTIFYING NEW TREATMENTS FOR THIS CHALLENGING DISEASE. 6.) A CARDIAC CELL MODEL TO EXAMINE DRUG INTERACTIONS WITH ALCOHOL, SINCE CARDIOTOXICITY IS THE LEADING REASON DRUGS FAIL TO SUCCESSFULLY MOVE FROM ANIMAL STUDIES TO HUMAN TREATMENT. 7.) USING A LIVER-BASED CELL CULTURE SYSTEM TO STUDY THE POTENTIALLY TOXIC EFFECTS OF MICROPLASTICS ON LIVER TISSUE. THIS YEAR'S FOCUS ON DEVELOPING MODELS TO AID DEVELOPMENT OF TREATMENTS UNDERSCORES THE TREMENDOUS POTENTIAL OF IN VITRO MODELS FOR BIOMEDICAL RESEARCH. BY SUPPORTING RESEARCH TO DEVELOP ALTERNATIVE, ANIMAL-FREE MODELS, ARDF CONTINUES TO ADVANCE BOTH ANIMAL WELFARE AND HUMAN HEALTH.ARDF ALSO SPONSORED SCIENTIFIC MEETINGS, AND EDUCATION AND OUTREACH ON ALTERNATIVE METHODS TO ACCELERATE UNDERSTANDING AND COLLABORATION. 478143 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 X 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 PA MN X X THE ORGANIZATION 2158878076 801 OLD YORK ROAD SUITE 218 JENKINTOWN PA 19046 SUE A LEARY PRESIDENT 12.00 35.00 X X 20000 65203 5942 NADIA S ADAWI BOARD MEMBER 0.50 0.50 X 0 0 0 ROBERT FINN BOARD MEMBER 0.50 0.50 X 0 0 0 FRANCIS KRAFCHIK BOARD MEMBER 0.50 0.50 X 0 0 0 JOSEPH LUDWIG VICE PRESIDENT 0.50 1.00 X X 0 0 0 AARON MCINTYRE TREASURER 0.50 1.00 X X 0 0 0 DENISE COWIE SECRETARY 0.50 1.00 X X 0 0 0 20000 65203 5942 1 0 0 0 MORGAN STANLEY 1585 BROADWAY NEW YORK NY 10036 INVESTMENT SERVICES 121976 1 77619 77619 185725 185725 2634274 2146750 487524 487524 487524 750868 0 0 673249 X 196937 196937 70000 70000 20000 20000 14071 3443 8265 2363 10267 6504 2820 943 3123 2061 821 241 17355 17355 121976 121976 136956 136834 93 29 10689 10036 593 60 18352 17739 613 12809 12809 600 600 141 106 35 RESEARCH AND INFORMATIO 1009 984 25 POSTAGE AND SHIPPING 140 90 50 634425 478143 152646 3636 690750 80052 403362 1044307 18075 4212 3358 12396 10896 2100 1500 10366590 12634377 408778 423277 11875792 14204946 72 7496 42392 8682 42464 16178 X 10943315 13229485 890013 959283 11833328 14188768 11875792 14204946 X 116443 2209727 29270 X X 0 1 X 1 0 X 136042 74498 69409 333654 77619 691222 136042 74498 69409 333654 77619 691222 691222 162080 141897 154090 140054 185725 783846 15549 8505 24054 1499122 0.46110 0.46110 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 0 15342 400 6419 400 21761 634025 3590638 634425 3612399 120164 330620 30041 82655 0 0 0 0 104056 106057 293887 330620 834620 1251930 46 90 22629 21761 44526 26014 26514 73472 82655 208655 312983 15679 15342 31021 10366590 2667787 400000 12634377 14214680 -3448036 400054 10366590 12674289 1890391 350000 14214680 10737802 2311583 375096 12674289 9074310 2033864 370372 10737802 1.00000 0.00000 0.00000 1 0 12396 10896 1500 1500 LEASE OBLIGATIONS 8682 8682 X 2867889 2209727 -92706 2117021 750868 0 750868 512449 0 512449 121976 121976 634425 PART V, LINE 4: THE ORGANIZATION'S QUASI-ENDOWMENT FUNDS FUND THE VARIOUS ACTIVITIES OF ARDF. THIS INCLUDES FUNDING RESEARCH PROJECTS THAT DEVELOP NON-ANIMAL ALTERNATIVES TO TRADITIONAL ANIMAL EXPERIMENTS AND SPONSORSHIP OF SCIENTIFIC MEETINGS PROMOTING ALTERNATIVES. PART X, LINE 2: MANAGEMENT BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX PROVISIONS TAKEN, AND AS SUCH, THE FOUNDATION DOES NOT HAVE ANY UNCERTIAN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: UNREALIZED GAIN ON BENEFICIAL INTEREST IN PERPETUAL TRUST 29,270. INVESTMENT FEES -121,976. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES GRANT PROGRAM MANAGEMENT 126937 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH GRANTS 70000 0 1 0 0 0 1 196937 0 196937 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DR. MORITZ PFEIFFENBERGER RESEARCH GRANT - FIRST STEPS TOWARD A FRACTURE HEMATOMA ON-A-CHIP MODEL 30000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DR. MATHIEU VINKEN RESEARCH GRANT - IN VITRO APPROACH FOR STYDING CHOLESTATIC POTENTIAL OF MICRO AND NANO PLASTICS 40000 WIRE TRANSFER 0 0 0 0 0 0 0 PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND THE FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. 1 UNIVERSTY OF CONNECTICUT HEALTH CENTER 263 FARMINGTON AVENUE FARMINGTON CT 06030 521725543 501(C)(3) 40000 0 DR. KSHITIZ RESEARCH GRANT - HIGHLY MATURED HUMAN CARDIAC MODELS TO MEASURE CARDIOTOXICITY UNIVERSTY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS 4333 BROOKLYN AVE NE SEATTLE WA 98195 916001537 501(C)(3) 40000 0 DR. VINCENZO CIRULLI RESEARCH GRANT - MODELING DIABITIES IN AN ORGANOID ON CHIP PLATFORM JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 615 NORTH WOLFE STREET BALTIMORE MD 21205 520595110 501(C)(3) 40000 0 DR. MAREN SCHENKE RESEARCH GRANT - ADVANCED NEUROTOXICITY TESTING WITH AN IN VITRO MODEL OF SEX DIFFERENCES ADA SCIENCE & RESEARCH INSTITUTE LLC 211 EAST CHICAGO AVENUE CHICAGO IL 60611 844338889 501(C)(3) 40000 0 DR. QUINN EASTER RESEARCH GRANT - PRECISION-CUT GINGIVAL SLICES AS AN ANIMAL-FREE MODEL OF ORAL INFLAMMATION JOHNS HOPKINS UNIVERSITY JHURA 10101 E 33RD STREET B001 BALTIMORE MD 21218 520595110 501(C)(3) 40000 0 DR. VENKATARAMANA SIDHAYE RESEARCH GRANT - DEVELOPING MODEL USING HUMAN LUNG SLICES TO STUDY COPD AND POTENTIAL DRUG THERAPEUTICS INSTITUTE FOR IN VITRO SCIENCES INC 30 W WATKINS MILL ROAD SUITE 100 GAITHERSBURG MD 20878 522029668 501(C)(3) 10000 0 SUPPORT OF IIVS EDUCATION AND OUTREACH PROGRAMS PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND A FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. FORM 990, PART V, LINE 24 AND PART IX SALARIES REFLECTED ON THE STATEMENT OF FUNCTIONAL EXPENSES INCLUDE ALLOCATIONS OF SALARIES AS A PORTION OF MANAGEMENT EXPENSES THAT THE ORGANIZATION PAYS TO ITS AFFILATE, THE AMERICAN ANTI-VIVISECTION SOCIETY. NOTE THAT THE ONE EMPLOYEE, SUE LEARY, IS PAID BY A COMMON PAYMASTER. THE ORGANIZATION'S AFFILIATE AMERICAN ANTI-VIVISECTION SOCIETY. THERE IS NO W-3 REPORTED FOR THIS ENTITY; ALL FILING REQUIREMENTS ARE MET THROUGH THE AFFILIATE AS MENTIONED. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT, TREASURER AND BOARD OF DIRECTORS REVIEW THE FORM 990 BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION FOLLOWS THE POLICIES OF ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS), WITH WHICH IT SHARES ITS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS MONITORS AND ENFORCES COMPLIANCE WITH THE CONFLICT OF INTEREST POLICIES (AS DETERMINED BY AAVS). ANNUAL DISCLOSURE FORMS ARE COLLECTED FROM EACH BOARD MEMBER AND REVIEWED BY THE PRESIDENT WHO ENSURES THAT MEMBERS RECUSE THEMSELVES FROM VOTING ON ANY MATTERS IN WHICH THEY MAY HAVE A DUAL INTEREST. THE BOARD OF DIRECTORS, EXCLUDING THE PRESIDENT, ENSURES THAT THE PRESIDENT RECUSES HERSELF IN CASE OF A POTENTIAL CONFLICT OF INTEREST. THE CONFLICT OF INTEREST POLICY EXPLICITLY DEEMS FAMILY AND BUSINESS RELATIONSHIPS TO HAVE POTENTIAL FOR CONFLICTS AND REQUESTS DETAILED INFORMATION ON ANY SUCH RELATIONSHIPS AS PART OF THE ANNUAL CONFLICT OF INTEREST POLICY PROCESS. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION'S COMPENSATION POLICIES ARE DICTATED BY ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS) WITH WHOM IT SHARES A BOARD OF DIRECTORS. THE BOARD OF DIRECTORS DETERMINES COMPENSATION OF THE PRESIDENT BY COMPARING WITH COMPENSATION OF EQUIVALENT POSITIONS USING PUBLICLY AVAILABLE DATA. NOTE THE PRESIDENT'S SALARY IS DETERMINED BY AAVS BUT IS REPORTED ON BOTH RETURNS. DECISIONS ARE RECORDED IN BOARD MINUTES AND MATERIALS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT LABOR: PROGRAM SERVICE EXPENSES 136,701. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 136,701. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 133. MANAGEMENT AND GENERAL EXPENSES 93. FUNDRAISING EXPENSES 29. TOTAL EXPENSES 255. FORM 990, PART XI, LINE 9: UNREALIZED LOSS ON BENEFICIAL INTEREST IN PERPETUAL TRUST 29,270. FORM 990, PART XII, LINE 2C: THERE WAS NO CHANGE IN THE AUDIT OVERSIGHT PROCESS FROM THE PRIOR YEAR. AMERICAN ANTI-VIVISECTION SOCIETY 801 OLD YORK ROAD NOBLE PLAZA SUITE JENKINTOWN PA 19046 230341990 EDUCATE THE PUBLIC ON PROBLEMS OF ANIMAL EXPERIMENTATION PA 501(C)(3) LINE 7 NONE 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 ALTERNATIVES RESEARCH AND DEVELOPMENT FOUNDATION 801 OLD YORK ROAD SUITE 218 JENKINTOWN PA 19046 232740843 0 400 400 634025 634425 120164 30041 0 0 0 AMERICAN ANTI-VIVISECTION SOCIETY INC 801 OLD YORK ROAD SUITE 204 JENKINTOWN PA 19046 230341990 15342 6019 21361 2956613 2977974 298899 74725 0 0 0